Prothena Corp Public (PRTA) Amortization of Deferred Charges (2021 - 2026)
Prothena Corp Public's (PRTA) quarterly Amortization of Deferred Charges came in at $734000.0 in Q1 2026, up 7.0% year-on-year from $686000.0 in Q1 2025, and up 1.38% quarter-over-quarter from $724000.0 in Q4 2025.
Prothena Corp Public (PRTA) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Prothena Corp Public's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $734000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 7.0% year-over-year to $734000.0 in Q1 2026; TTM through Mar 2026 was $2.9 million, a 5.51% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 4.27% from the prior year.
- Amortization of Deferred Charges rose to $734000.0 in Q1 2026 per PRTA's latest filing, from $724000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.3 million in Q4 2023 and bottomed at $662000.0 in Q2 2024.
- The 5-year median for Amortization of Deferred Charges is $734000.0 (2026), against an average of $1.2 million.
- Across the five-year window, Amortization of Deferred Charges soared 47.81% in 2023 and sank 69.42% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $1.5 million in 2022, then surged by 47.81% to $2.3 million in 2023, then sank by 69.42% to $692000.0 in 2024, then climbed by 4.62% to $724000.0 in 2025, then grew by 1.38% to $734000.0 in 2026.
- Per Business Quant, the three latest PRTA Amortization of Deferred Charges figures stand at $734000.0 (Q1 2026), $724000.0 (Q4 2025), and $714000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 734,000.00 |
| Mar 31, 2026 | 734,000.00 |
| Dec 31, 2025 | 724,000.00 |
| Dec 31, 2025 | 724,000.00 |
| Sep 30, 2025 | 714,000.00 |
| Sep 30, 2025 | 714,000.00 |
| Jun 30, 2025 | 683,000.00 |
| Jun 30, 2025 | 683,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Dec 31, 2024 | 692,000.00 |
| Dec 31, 2024 | 692,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Jun 30, 2024 | 662,000.00 |
| Jun 30, 2024 | 662,000.00 |
| Mar 31, 2024 | 672,000.00 |
| Mar 31, 2024 | 672,000.00 |
| Dec 31, 2023 | 2.26 Mn |
| Dec 31, 2023 | 2.26 Mn |